Jonathan West

Jonathan West

Auto-generated profile, based on publicly available information

Jonathan West

Department of Surgery Tauranga Hospital Tauranga New Zealand

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JWJonathan West
Jonathan West
SOSimon Ogston
Simon Ogston
JFJohn Foerster
John Foerster
Methotrexate (MTX) has been used to treat psoriasis for over half a century. Even so, clinical data characterising its efficacy and safety are sparse. In order to enhance the available evidence, we conducted two meta-analyses, one for efficacy and one for safety outcomes, respectively, according to PRISMA checklist. (Data sources, study criteria, and study synthesis methods are detailed in Methods). In terms of efficacy, only eleven studies met criteria for study design and passed a Cochrane risk of bias analysis. Based on this limited dataset, 45.2% [95% confidence interval 34.1–60.0] of patients achieve PASI75 at primary endpoint (12 or 16 weeks, respectively, n = 705 patients across all studies), compared to a calculated PASI75 of 4.4 [3.5–5.6] for placebo, yielding a relative risk of 10.2 [95% C.I. 7.1–14.7]. For safety outcomes, we extended the meta-analysis to include studies employing the same dose range of MTX for other chronic inflammatory conditions, e.g. rheumatoid arthritis, in order not to maximise capture of relevant safety data. Based on 2763 patient safety years, adverse events (AEs) were found treatment limiting in 6.9 ± 1.4% (mean ± s.e.) of patients treated for six months, with an adverse effect profile largely in line with that encountered in clinical practice. Finally, in order to facilitate prospective clinical audit and to help generate long-term treatment outcomes under real world conditions, we also developed an easy to use documentation form to be completed by patients without requirement for additional staff time. Meta-analyses for efficacy and safety, respectively, employed non-identical selection criteria. These meta-analyses summarise currently available evidence on MTX in psoriasis and should be of use to gauge whether local results broadly fall within outcomes.

23 October 2017 in npj Vaccines
Verified
Journal Article
Open access
PDF file
AZAndris Zeltins
Andris Zeltins
JWJonathan West
Jonathan West
FZFranziska Zabel
Franziska Zabel
AEAadil El-Turabi
Aadil El-Turabi
IBIna Balke
Ina Balke
Martin BachmannMartin Bachmann
Martin Bachmann
Monoclonal antibodies are widely used to treat non-infectious conditions but are costly. Vaccines could offer a cost-effective alternative but have been limited by sub-optimal T-cell stimulation and/or weak vaccine responses in recipients, for example, in elderly patients. We have previously shown that the repetitive structure of virus-like-particles (VLPs) can effectively bypass self-tolerance in therapeutic vaccines. Their efficacy could be increased even further by the incorporation of an epitope stimulating T cell help. However, the self-assembly and stability of VLPs from envelope monomer proteins is sensitive to geometry, rendering the incorporation of foreign epitopes difficult. We here show that it is possible to engineer VLPs derived from a non human-pathogenic plant virus to incorporate a powerful T-cell-stimulatory epitope derived from Tetanus toxoid. These VLPs (termed CMVTT) retain self-assembly as well as long-term stability. Since Th cell memory to Tetanus is near universal in humans, CMVTT-based vaccines can deliver robust antibody-responses even under limiting conditions. By way of proof of concept, we tested a range of such vaccines against chronic inflammatory conditions (model: psoriasis, antigen: interleukin-17), neurodegenerative (Alzheimer’s, β-amyloid), and allergic disease (cat allergy, Fel-d1), respectively. Vaccine responses were uniformly strong, selective, efficientin vivo, observed even in old mice, and employing low vaccine doses. In addition, randomly ascertained human blood cells were reactive to CMVTT-VLPs, confirming recognition of the incorporated Tetanus epitope. The CMVTT-VLP platform is adaptable to almost any antigen and its features and performance are ideally suited for the design of vaccines delivering enhanced responsiveness in aging populations.

17 May 2017 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
JWJ. West
J. West
SOS. Ogston
S. Ogston
JBJ. Berg
J. Berg
CPC. Palmer
C. Palmer
CFC. Fleming
C. Fleming
JFJohn Foerster
John Foerster

14 June 2018 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
KBK. Boswell
K. Boswell
HCH. Cameron
H. Cameron
JWJ. West
J. West
CFC. Fleming
C. Fleming
SISally Ibbotson
Sally Ibbotson
JFJohn Foerster
John Foerster

3 August 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JFJohn Foerster
John Foerster
KBKirsty Boswell
Kirsty Boswell
JWJonathan West
Jonathan West
HCHeather Cameron
Heather Cameron
CFColin Fleming
Colin Fleming
RDRobert Dawe
Robert Dawe
Narrowband NB-UVB phototherapy (NB-UVB) is an effective treatment for psoriasis, as demonstrated by clinical trials. However, due to required infrastructure and need for treatment attendance opinions on the value of offering this treatment in routine practice vary. AIMS: To provide high quality large-scale and long-term data on the efficacy of NB-UVB for psoriasis under real-world conditions in order to assist in management decisions. The following resources were employed: (1) complete and prospectively recorded prescription drug records for a population of 420,000 marked by low demographic mobility, (2) prospectively recorded clinical treatment outcomes for all NB-UVB treatment episodes occurring in the local population; (3) complete dermatology electronic treatment records of all psoriasis patients, allowing cross-validation of diagnoses and treatment records. Using these data sets, we analysed all first-ever initial NB-UVB treatment episodes occurring over 79 months (n = 1749) for both clinical outcomes and the effect of NB-UVB on the use of topical treatments for psoriasis. Around 75% of patients both achieved a status of “clear/minimal disease” and used fewer topical treatments. NB-UVB treatment led to a strong reduction for both steroid creams (25%) and psoriasis-specific topicals, e.g. vitamin-D products (30%) during the 12-month period following NB-UVB treatment. The effects measured were specific as no effect of NB-UVB was noted on drug prescriptions unrelated to psoriasis. Results were independent of individuals administering and/or scoring treatment, as they were highly similar between four geographically separate locations. NB-UVB treatment is highly effective and leads to a remarkable reduction in the need for topical cream treatments for a period of at least 12 months.

6 February 2016 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JWJ. West
J. West
SOS. Ogston
S. Ogston
CPC. Palmer
C. Palmer
CFC. Fleming
C. Fleming
RDR. Dawe
R. Dawe
JFJohn Foerster
John Foerster